

CONTENTS

CONTRIBUTORS	xi
FOREWORD <i>R. John Ellis</i>	xix
PREFACE	xxv
ACKNOWLEDGMENTS	xxvii
INTRODUCTION TO THE WILEY SERIES ON PROTEIN AND PEPTIDE SCIENCE <i>Vladimir N. Uversky</i>	xxix

PART I PRINCIPLES OF PROTEIN MISFOLDING

1 Why Proteins Misfold <i>Silvia Campioni, Elodie Monsellier, and Fabrizio Chiti</i>	3
2 Endoplasmic Reticulum Stress and Oxidative Stress: Mechanisms and Link to Disease <i>Jyoti D. Malhotra and Randal J. Kaufman</i>	21
3 Role of Molecular Chaperones in Protein Folding <i>Kausik Chakraborty, Florian Georgescu, Manajit Hayer-Hartl, and F. Ulrich Hartl</i>	47
4 Kinetic Models for Protein Misfolding and Association <i>Evan T. Powers and Frank A. Ferrone</i>	73

5	Toxicity in Amyloid Diseases	93
	<i>Massimo Stefani</i>	
6	Autophagy: An Alternative Degradation Mechanism for Misfolded Proteins	113
	<i>Maria Kon and Ana Maria Cuervo</i>	
7	Role of Posttranslational Modifications in Amyloid Formation	131
	<i>Andisheh Abedini, Ruchi Gupta, Peter Marek, Fanling Meng, Daniel P. Raleigh, Humeyra Taskent, and Sylvia Tracz</i>	
8	Unraveling Molecular Mechanisms and Structures of Self-Perpetuating Prions	145
	<i>Peter M. Tessier and Susan Lindquist</i>	
9	<i>Caenorhabditis elegans</i> as a Model System to Study the Biology of Protein Aggregation and Toxicity	175
	<i>Elise A. Kikis, Anat Ben-Zvi, and Richard I. Morimoto</i>	
10	Using <i>Drosophila</i> to Reveal Insight Into Protein Misfolding Diseases	191
	<i>Julide Bilen and Nancy M. Bonini</i>	
11	Animal Models to Study the Biology of Amyloid-β Protein Misfolding in Alzheimer Disease	213
	<i>Karen H. Ashe</i>	
PART II PROTEIN MISFOLDING DISEASE: GAIN-OF-FUNCTION AND LOSS-OF-FUNCTION DISEASES		
12	Alzheimer Disease: Protein Misfolding, Model Systems, and Experimental Therapeutics	233
	<i>Donald L. Price, Alena V. Savonenko, Tong Li, Michael K. Lee, and Philip C. Wong</i>	
13	Prion Disease Therapy: Trials and Tribulations	259
	<i>Valerie L. Sim and Byron Caughey</i>	
14	Misfolding and Aggregation in Huntington Disease and Other Expanded Polyglutamine Repeat Diseases	305
	<i>Ronald Wetzel</i>	
15	Systemic Amyloidoses	325
	<i>Marina Ramirez-Alvarado and Joel N. Buxbaum</i>	

16 Hemodialysis-Related Amyloidosis	347
<i>David P. Smith, Alison E. Ashcroft, and Sheena E. Radford</i>	
17 Copper-Zinc Superoxide Dismutase, Its Copper Chaperone, and Familial Amyotrophic Lateral Sclerosis	381
<i>Duane D. Winkler, Mercedes Prudencio, Celeste Karch, David R. Borchelt, and P. John Hart</i>	
18 Alpha-1-Antitrypsin Deficiency	403
<i>David A. Lomas and David H. Perlmutter</i>	
19 Folding Biology of Cystic Fibrosis: A Consortium-Based Approach to Disease	425
<i>William E. Balch, Ineke Braakman, Jeff Brodsky, Raymond Frizzell, William Guggino, Gergely L. Lukacs, Christopher Penland, Harvey Pollard, William Skach, Eric Sorscher, and Philip Thomas</i>	
20 Thiopurine S-Methyltransferase Pharmacogenomics: Protein Misfolding, Aggregation, and Degradation	453
<i>Fang Li and Richard M. Weinshilboum</i>	
21 Gaucher Disease	469
<i>Tim Edmunds</i>	
22 Cataract as a Protein-Aggregation Disease	487
<i>Yongting Wang and Jonathan A. King</i>	
23 Islet Amyloid Polypeptide	517
<i>Andisheh Abedini and Daniel P. Raleigh</i>	
PART III ROLE OF ACCESSORY MOLECULES AND RISK FACTORS	
24 Role of Metals in Alzheimer Disease	545
<i>Blaine R. Roberts and Ashley I. Bush</i>	
25 Why Study the Role of Heparan Sulfate in In Vivo Amyloidogenesis?	559
<i>Robert Kisilevsky and John Ancsin</i>	
26 Serum Amyloid P Component	571
<i>Simon Kolstoe and Steve Wood</i>	
27 Role of Oxidatively Stressed Lipids in Amyloid Formation and Toxicity	585
<i>Paul H. Axelsen and Hiroaki Komatsu</i>	

28	Role of Oxidative Stress in Protein Misfolding and/or Amyloid Formation	615
	<i>Johanna C. Scheinost, Daniel P. Witter, Grant E. Boldt, and Paul Wentworth, Jr.</i>	
29	Aging and Aggregation-Mediated Proteotoxicity	631
	<i>Ehud Cohen and Andrew Dillin</i>	
 PART IV MEDICAL ASPECTS OF DISEASE: DIAGNOSIS AND CURRENT THERAPIES		
30	Imaging of Misfolded Proteins	647
	<i>Harry LeVine, III</i>	
31	Diagnosis of Systemic Amyloid Diseases	673
	<i>Morie A. Gertz</i>	
32	Identification of Biomarkers for Diagnosis of Amyloid Diseases: Quantitative Free Light-Chain Assays	689
	<i>Jerry A. Katzmann</i>	
33	Real-Time Observation of Amyloid-β Fibril Growth by Total Internal Reflection Fluorescence Microscopy	699
	<i>Tadato Ban and Yuji Goto</i>	
34	Current and Future Therapies for Alzheimer Disease	711
	<i>Paramita Chakrabarty, Pritam Das, and Todd E. Golde</i>	
35	Current Therapies for Light-Chain Amyloidosis	775
	<i>Angela Dispenzieri and Shaji Kumar</i>	
36	Familial and Senile Amyloidosis Caused by Transthyretin	795
	<i>Steven R. Zeldenrust and Merrill D. Benson</i>	
37	Identifying Targets in α-Synuclein Metabolism to Treat Parkinson Disease and Related Disorders	817
	<i>Julianna Tomlinson, Valerie Cullen, and Michael G. Schlossmacher</i>	
38	Emerging Molecular Targets in the Therapy of Dialysis-Related Amyloidosis	843
	<i>Gennaro Esposito and Vittorio Bellotti</i>	
39	Familial Amyloidosis Caused by Lysozyme	867
	<i>Mireille Dumoulin</i>	

40	Therapeutic Prospects for Polyglutamine Disease	887
	<i>Maria Pennuto and Kenneth H. Fischbeck</i>	
 PART V APPROACHES FOR NEW AND EMERGING THERAPIES		
41	Chemistry and Biology of Amyloid Inhibition	905
	<i>Mark A. Findeis</i>	
42	Immunotherapy in Secondary and Light-Chain Amyloidosis	917
	<i>Jonathan Wall</i>	
43	Anti-Misfolding and Anti-Fibrillization Therapies for Protein Misfolding Disorders	933
	<i>Zane Martin and Claudio Soto</i>	
44	Therapies Aimed at Controlling Gene Expression, Including Up-Regulating a Chaperone or Down-Regulating an Amyloidogenic Protein	945
	<i>Gregor P. Lotz and Paul J. Muchowski</i>	
45	Understanding and Ameliorating the TTR Amyloidoses	967
	<i>Steven M. Johnson, R. Luke Wiseman, Natàlia Reixach, Johan F. Paulsson, Sungwook Choi, Evan T. Powers, Joel N. Buxbaum, and Jeffery W. Kelly</i>	
	INDEX	1005